Status:
TERMINATED
Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Solid Tumor
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
Brief Summary
This study is dose escalation study to evaluate the tolerability and safety of ONO-7914 alone and in combination with ONO-4538 in patients with advanced or metastatic solid tumors
Eligibility Criteria
Inclusion
- Patients with advanced or metastatic solid tumor
- Patients with ECOG performance status of 0 or 1
- Patients with a life expectancy of at least 3 months
Exclusion
- Patients with severe complication
- Patients judged to be incapable of providing consent for reasons such as concurrent dementia
Key Trial Info
Start Date :
February 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 26 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06535009
Start Date
February 8 2022
End Date
February 26 2025
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan